While clinical trials for FDA approval for use of GLP-1/GIP medications in the treatment of T1D are ongoing, the consensus statement emphasizes several key principles for safe use in the meantime: Insulin safety comes first People with type 1 diabetes should never stop taking insulin while using a GLP-1 or GIP medication
Ogura, Y., Kitada, M., Xu, J., Monno, I
You get massive proliferation of brand-new cells followed by aggressive maturation of those cells into permanent, rock-hard muscle tissue
Among these agents, semaglutide and liraglutide have consistently shown the strongest cardiovascular benefit, with semaglutide showing additional promise in patients with obesity and HFpEF
And remember, teamwork makes the dream work